Ilant Health launched out of stealth Tuesday. The company serves employers and payers and helps identify patients in need of obesity treatment and matches them to the care best for them.

Midi Health’s Series A funding round was led by Google Ventures. In total, Midi Health has raised $40 million, including from Felicis, Semper Virens, Icon, 25M and Operator Collective. The company offers virtual care for those going through perimenopause or menopause.

Evvy’s $14 million funding round was led by Left Lane Capital and included participation from General Catalyst, LabCorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue and Amboy Street Ventures. In total, Evvy has raised $19 million. 

Global funding for digital health companies finally stabilized in Q1 of this year. The sector raised $3.4 billion — this marks the first time the digital health world didn’t experience a quarter-over-quarter funding decline since Q4 of 2021. By holding steady, digital health startups defied the dwindling fundraising totals seen across the broader venture capital landscape, where funding dropped by 13% quarter-over-quarter.

MedArrive’s new $8 million funding was led by Cobalt Ventures, a subsidiary of Blue Cross and Blue Shield of Kansas City. With the funding, the company will grow its team, as well as improve on its product and technology, said Dan Trigub, CEO and co-founder of MedArrive.

Kindbody’s $100 million funding, announced last week, was led by Perceptive Advisors. It brings the company’s total equity and debt funding to more than $290 million and its valuation to $1.8 billion. It will use the money to add 10 new locations.

The funding round was led by Distributed Ventures and included participation from Idealab NY and Elements Health Ventures. Tuned plans to use the funding to contract with more employers and third party administrators, said Danny Aronson, co-founder and CEO of the startup.

New York healthcare startups received $3.9 billion of funding in 2022, compared to $9 billion in 2021, according to a new DHNY report. Biotech startups represented 22% of total funding in 2022, a stark difference from women’s health only representing 2%.

The $58 million funding round was led by Portage and included participation from PruVen Capital, Wing Venture Capital and others. With the funding, Angle Health plans to expand into additional markets and grow its membership.

Override provides chronic pain patients with a care team that includes a pain physician, a physical therapist, a psychologist and a coach. The company has received $3.5 million in seed funding and has acquired Take Courage Coaching.

The funding was led by Bold Capital Group. Other investors of the company include Khosla Ventures, WestRiver Group and Glico. In total, Viome has raised more than $150 million.

This funding round was led by Bain Capital Life Sciences and SV Health Investors. They join existing investors, including Bill Gates and Access Biotechnology. The money will be used to support several clinical trials.

Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.

Government-funded initiatives such as the Cancer Moonshot support not only the primary science that often serves as a foundation for medical advances, but also ensure that patients with rare cancers are not overlooked.

Ceryx’s device, Cysoni, is designed to pace the heart in rhythm with a person’s respiration, so that the heart rate and breathing are synced. This is typically the case for a healthy person, but for someone with heart failure, that link becomes severed, CEO Stuart Plant said.

The DNA currently used in genetic medicines research is synthesized by chemical methods. Ansa Biotechnologies employs faster and less expensive enzymes-based technology, and the startup has raised capital to scale up operations as it prepares to launch its service.

Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to kill bacteria. The Princeton University spinout says its approach could overcome the drug resistance bacteria are developing to currently available products.

The funding round was led by Wellington Management. The company sees its approach as a break from the industry’s “disproportionate” focus on dialysis, which is used to treat people with kidney failure.

The company currently operates two centers, one in Cincinnati and the other in Crescent Springs, Kentucky. The Series A funding round led by JAZZ Venture Partners will allow the company to open new locations as well as offering virtual care.

Transformation Capital led the funding round with participation from Andreessen Horowitz, Frist Cressey Ventures, Edward Elmhurst Health, AlleyCorp. The new financing enables Memora to meet commercial demand , drive new partnerships and further improve the care delivery experience, said CEO Manav Sevak.

Ada Health closed its Series B round after a $30 million extension round. International investors Farallon Capital, Red River West and Bertelsmann Investments provided the additional funds. This follows an initial Series B raise of $90 million last May, which was led by Bayer’s investment arm.

The Series A financing round was led by F-Prime Capital, with existing investors Lerer Hippeau, NextView Ventures and Amplifyher Ventures also participating. The money will be invested in its platform, hiring additional speech-language pathologists, and partnering with more providers and health plans.

Funding for 2021 was up 150% from the previous record of $3.6 billion raised in 2020, according to the 2022 New York Healthcare Innovation Report. Digital health startups in areas including virtual care, patient engagement and mental health captured 87% of funds.

The new infusion brings Wheel’s total funding to $216 million at a time when more companies understand the need to have an on-demand consumer/patient-facing telemedicine service that Wheel possesses but may not necessarily want to build it from the ground up.

The company, which pulls together information on clinicians and researchers, recently closed a funding round led by Altimeter Capital. It plans to use the funds to build out more features and grow its network.

The company is developing a digital therapeutic using VR to manage chronic lower back pain. It recently submitted an application for de novo clearance to the FDA. 

The company, which offers an AI platform that provides personalized health coaching for chronic disease patients, will use the new funds to invest in research and development and to expand its virtual integrations with health plans and employers.

Though the Medicare Advantage-focused insurance technology startup is smaller than rivals like Clover Health in terms of membership and revenues, this latest financing round places it ahead of, or at least on par with, several larger competitors with regard to total funds raised.

Brave Care leverages its technology and data platform to provide primary and urgent care for children. It provides care remotely and through its five brick-and-mortar clinics, which it plans to expand to 100 in the next few years.

Elligo Health Research uses EHR data, technology and services to expand patient access to clinical trials. It will use the new funds to further invest in its technology platform and purchase research practice management company ClinEdge.